BenzingaOctober 13, 2026 at 3:48 AM NY14 Days Ago
Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36
Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
